Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term hematological reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at -80 degrees C in a mechanical freezer.
Galmes A, Gutiérrez A, Sampol A, Canaro M, Morey M, Iglesias J, Matamoros N, Duran MA, Novo A, Bea MD, Galán P, Balansat J, Martínez J, Bargay J, Besalduch J. Galmes A, et al. Among authors: besalduch j. Haematologica. 2007 Jul;92(7):986-9. doi: 10.3324/haematol.11060. Haematologica. 2007. PMID: 17606452 Free article.
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: besalduch j. Haematologica. 2002 Feb;87(2):154-66. Haematologica. 2002. PMID: 11836166 Clinical Trial.
Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.
Gutierrez A, Rodriguez J, Martinez-Serra J, Gines J, Paredes P, Garcia F, Vercher J, Balanzat J, Del Campo R, Galan P, Morey M, Sampol A, Novo A, Bento L, García L, Bargay J, Besalduch J. Gutierrez A, et al. Among authors: besalduch j. Onco Targets Ther. 2014 Nov 13;7:2093-100. doi: 10.2147/OTT.S70264. eCollection 2014. Onco Targets Ther. 2014. PMID: 25419147 Free PMC article.
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
Lahuerta JJ, Mateos MV, Martínez-López J, Grande C, de la Rubia J, Rosiñol L, Sureda A, García-Laraña J, Díaz-Mediavilla J, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Oriol A, Escoda L, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF; Grupo Español de MM and Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups. Lahuerta JJ, et al. Among authors: besalduch j. Haematologica. 2010 Nov;95(11):1913-20. doi: 10.3324/haematol.2010.028027. Epub 2010 Jul 27. Haematologica. 2010. PMID: 20663944 Free PMC article. Clinical Trial.
Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
Serra JM, Gutiérrez A, Alemany R, Navarro M, Ros T, Saus C, Ginés J, Sampol A, Amat JC, Serra-Moisés L, Martín J, Galmés A, Vögler O, Besalduch J. Serra JM, et al. Among authors: besalduch j. Mol Pharmacol. 2008 Jun;73(6):1679-87. doi: 10.1124/mol.107.043372. Epub 2008 Mar 19. Mol Pharmacol. 2008. PMID: 18353995
93 results